Aldeyra Therapeutics (FRA:137) Short Interest


FRA:137 Aldeyra Therapeutics Inc FRA:137
29 GF Score
Price €1.63
! 2 Warning Signs
View Full Analysis

What is Aldeyra Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:137 vs CGTX, RANI, PEPG: Short Interest Comparison

For the Biotechnology subindustry, Aldeyra Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aldeyra Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aldeyra Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Aldeyra Therapeutics's Short Interest falls into.


FRA:137
29GF Score
Aldeyra Therapeutics Inc FRA:137
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aldeyra Therapeutics Business Description

Other Exchanges ALDX:USA137:Germany
Address 131 Hartwell Avenue, Suite 320, Lexington, MA, USA, 02421
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
29GF Score

Get the complete analysis for FRA:137

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.63
Price